25 After 12 months of treatment, a significant reduction in the mean VAS scores for pain was observed in patients treated with ALC, compared with the placebo group
Benefits PT-141 is believed to help with: Braincentered desire support: By acting on melanocortin receptors in the hypothalamus, PT141 can improve subjective desire, arousal, and satisfactionaddressing the want to rather than just the can. Ondemand flexibility: Typically dosed as a subcutaneous injection about 45 minutes before anticipated activity, allowing clients to plan special moments without daily medication. Hormonesparing option: PT141 does not require systemic estrogen or testosterone and can be attractive for clients who are not candidates for or do not wish to use hormone therapy. Potential for both women and men: FDA approval is specific to premenopausal women with HSDD, but emerging clinical practice and research describe benefits in broader female populations and in men with libido or erectile issues, always offlabel and carefully consented.
Key Outcomes: Up to 24.2% total body weight reduction in high-dose groups
Adults need 2.4 micrograms (mcg) daily, with slightly higher amounts during pregnancy or chestfeeding
Both medications are HSA/FSA eligible, and no insurance or membership fees are required
:max_bytes(150000):strip_icc()/benefits-of-glutathione-89457_final-01-502464fe91b2444285b0cccf8cb0a33c.png)
